Recently, immune checkpoint inhibitors have emerged as one of the promising class of immunotherapy approaches in the management of cancer.
Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
- Global & Regional Combination Cancer Immunotherapy Market Insight Till 2028
- Combination Cancer Immunotherapy Market By Different Cancers
- Patent, Price & Dosage Analysis On Approved Combination Drugs
- Global & Regional Sales Insights On Approved Combination Drugs Till 2028
- Insight on 600 Combination Cancer Immunotherapy Drugs In Clinical Trials
- Insight on 45 Combination Cancer Immunotherapy Drugs Commercially Approved In Market
- Clinical Trials & Patent Insight By Company, Country, Indication & Phase
Download Report:
https://www.kuickresearch.com/report-combination-cancer-therapy-market
Recently, immune checkpoint inhibitors have emerged as one of the promising class of immunotherapy approaches in the management of cancer. Till date, several immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen (CTLA-4) and programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) have gained entry into the market for the management of wide range of cancers. Though their success is mainly hampered by their resistance and treatment related adverse events. To mitigate these challenges, research studies have focused on utilizing the immune checkpoint inhibitor therapy in combination with other cancer targeting regimens including chemotherapy, monoclonal antibodies, small molecule inhibitors, or other immune checkpoint inhibitors. The combinational approach combines two or more drugs which have synergistic action on the target cell, thereby increasing the efficacy of these drugs.
The encouraging response of immune checkpoint inhibitors in combination therapy has surged their rapid entry into the market. For instance, US FDA has granted approval to atezolizumab and durvalumab in combination with chemotherapy for the management of small cell lung cancer. Further in 2021, regulatory bodies have also granted approval to fixed-dose combination of relatlimab (LAG-3 inhibitor) plus nivolumab for the treatment of adult and pediatric patients who are 12 years of age or older and who have unresectable or metastatic melanoma. The combination is sold under the trade name Opdualag and is marketed by Bristol Myers Squibb. More recently in 2022, EMA has approved Keytruda and chemotherapy combination as neoadjuvant therapy in the treatment of triple negative breast cancer. All these combinational therapies have demonstrated significant improve in overall survival rates and progression free survival rate in clinical trials.
Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028 Report Highlights:
- Global Immune Checkpoint Inhibitors Market Opportunity: > USD 30 Billion
- Immune Checkpoint Inhibitors Clinical Trials Insight: CTLA-4, LAG3, PD-1/PD-L1, TIGIT Inhibitors
- Immune Checkpoint Inhibitors Clinical Trials Insight: > 300 Drugs In Trials
- Biomarkers sourced During clinical Trials
- Biomarkers Insight By Immune Checkpoint Inhibitors Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Immune Checkpoint Inhibitor Drug
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report:
https://www.kuickresearch.com/report-immune-checkpoint-inhibitors-biomarkers
Although only a few combinations have been granted approval, the future of combinational therapy is highly promising which is mainly attributed to large number of ongoing clinical trials. For instance, researchers have initiated phase-I clinical trial to evaluate the combination of Tiragolumab with Atezolizumab in wide range of cancers including esophageal cancer, non-small cell lung cancer, myeloma, non-Hodgkin lymphoma, and squamous cell carcinoma. The preliminary results from the trial demonstrated that the combination appeared to be tolerable, with clinical activity seen in patients with esophageal cancer, who had not received immunotherapy, and durable responses were seen as a consequence and based in large part on this study. In addition to this, ongoing clinical trials are also evaluating the role of immune checkpoint inhibitors with other small molecule inhibitors including EFGR, BTK, P13K, CDK4/6, VEGF, MEK, amongst others. The preliminary results from these trials have shown promising results, thus suggesting bright future of combinational immunotherapy.
The promising response of immune checkpoint inhibitors in combinational therapy has gained interest from large pharmaceutical giants. The key players in the market have entered into partnerships, collaboration, or joint ventures to analyze different combinations to enhance the efficacy of immune checkpoint inhibitors as combinational therapies. Recently in May, 22 AUM Biosciences has announced clinical trial and supply agreement 3with Roche. The collaboration will access the safety and tolerability of AUM001, highly selective MNK1/2 inhibitor in combination with Tecentriq in various solid tumors such as non-small cell lung cancer, and urothelial cancer.
As per our report findings, the global combinational immunotherapy market is expected to surpass US$ 15 Billion by 2028. The major factor driving the growth of market are the rising incidences of cancer, unmet need of targeted therapies, and higher adoption rates of immunotherapeutic approaches. Moreover, the promising response of combinational immunotherapy and their ability to overcome the limitations of targeted therapies is another factor propelling the growth of market. In addition, rising investment by pharmaceutical giants to conduct clinical trials in this segment is also boosting the growth of market.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com